Literature DB >> 27453421

MicroRNA-618 modulates cell growth via targeting PI3K/Akt pathway in human thyroid carcinomas.

L Yi1, Y Yuan1.   

Abstract

OBJECTIVE: MicroRNAs (miRNAs) were popularly investigated in many cancers. The aim of this study was to evaluate the expression, role, and mechanism of microRNA-618 (miR-618) in human thyroid cancer (TC) cells.
MATERIALS AND METHODS: Quantitative real-time polymerase chain reaction was carried out to examine the expression level of miR-618 in 20 TC tissues with 15 adjacent normal tissues. Synthesized mimics medicated miR-618 overexpression model was done in TC TPC-1 cell line. The effects of cell growth were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide method. In addition, PI staining followed by flow cytometry was performed to analyze cell cycle. Then, we performed Western blotting to analyze the impact of miR-618 overexpression on the classical PI3K/Akt signaling pathway.
RESULTS: We confirmed previous findings that miR-618 was downregulated in TC. Functionally, we found that forced expression of miR-618 suppressed cell proliferation and led to G2/M arrest in TPC-1 cells. Mechanically, we showed that miR-618 overexpression induced a significant inhibition of PI3K/Akt signaling pathway in TPC-1 cells. Importantly, restoration of Akt reversed the growth inhibitory effects of miR-618.
CONCLUSION: Taken together, our results described a growth-suppressive role of miR-618 in TC cells partially targeting the PI3K/Akt signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 27453421     DOI: 10.4103/0019-509X.186577

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  8 in total

Review 1.  Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes.

Authors:  Maryam Zarkesh; Azita Zadeh-Vakili; Fereidoun Azizi; Forough Foroughi; Maziar Mohammad Akhavan; Mehdi Hedayati
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

2.  A miRNA signature suggestive of nodal metastases from laryngeal carcinoma.

Authors:  F Ricciardiello; R Capasso; H Kawasaki; T Abate; F Oliva; A Lombardi; G Misso; D Ingrosso; C A Leone; M Iengo; M Caraglia
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-12       Impact factor: 2.124

3.  Long Non-Coding RNA HOTAIR Modulates KLF12 to Regulate Gastric Cancer Progression via PI3K/ATK Signaling Pathway by Sponging miR-618.

Authors:  Jin Xun; Chunfeng Wang; Jianning Yao; Bing Gao; Lianfeng Zhang
Journal:  Onco Targets Ther       Date:  2019-11-27       Impact factor: 4.147

4.  MicroRNA-618 Directly Targets Metadherin mRNA To Suppress The Malignant Phenotype Of Osteosarcoma Cells By Reducing PTEN-AKT Pathway Output.

Authors:  Bohan Li; Jie Zhao; Qian Zhao; Dongjin Wu; Cheng Zhang; Kun Zhao; Yang Song; Chunzheng Gao
Journal:  Onco Targets Ther       Date:  2019-11-15       Impact factor: 4.147

5.  Polymorphism rs2682818 participates in the progression of colorectal carcinoma via miR-618-TIMP1 regulatory axis.

Authors:  Wei Shao; Haina Xia; Qiangfang Lan; Jialu Gu; Haidong Huang; Fei Zheng; Youyou Zheng
Journal:  Sci Rep       Date:  2021-11-30       Impact factor: 4.379

6.  Long intergenic non-protein coding RNA 511 promotes the progression of osteosarcoma cells through sponging microRNA 618 to upregulate the expression of maelstrom.

Authors:  Wen Guo; Qing Yu; Ming Zhang; Fang Li; Yu Liu; Weiwei Jiang; Haitao Jiang; Haijun Li
Journal:  Aging (Albany NY)       Date:  2019-08-06       Impact factor: 5.682

7.  hsa-miR-195-5p inhibits cell proliferation of human thyroid carcinoma cells via modulation of p21/cyclin D1 axis.

Authors:  Dexin Liu; Ping Li; Xiaodong Wang; Wei Wang
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

8.  Circulating miR-618 Has Prognostic Significance in Patients with Metastatic Colon Cancer.

Authors:  Maria Radanova; Galya Mihaylova; Zhasmina Mihaylova; Desislava Ivanova; Oskan Tasinov; Neshe Nazifova-Tasinova; Pavel Pavlov; Milko Mirchev; Nikolay Conev; Ivan Donev
Journal:  Curr Oncol       Date:  2021-03-15       Impact factor: 3.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.